Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06665568 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients

Study acronym: Keta-Care
StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 0 to 1v4
  2. Start date: Nov 2024 to Apr 2025v3
  3. Eligibility criteria expanded, about 54 words Secondary endpoints: details revised at 7 of 7 entriesv2 Show 1 more changeShow less
    • Secondary endpoints: details revised at 7 of 7 entries

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Zurich
157 trials monitored
See 3 trials at risk
Depression
2,998 trials monitored
See 166 trials at risk
Anxiety
2,264 trials monitored
See 97 trials at risk
With progression of cancer, patients and their caregivers experience challenging emotional distress, which can make them feel depressed and very anxious. Patients with advanced cancer often do not have long to live. However, most antidepressants take a long time to act and cause unwanted side effects. There is hence a need for a fast acting antidepressant with fewer unwanted side effects. Ketamine is an effective and fast acting antidepressant originating from pain treatment, which has few unwanted side effects. It can be taken by a patient as a nasal spray when it is needed. The idea of treating depression and anxiety in cancer patients in palliative care with ketamine nasal spray is new. How effective ketamine will be at reducing depression and anxiety in patients is unknown . It is also unknown whether this kind of treatment will be safe and practical for palliative care patients. This study aims to answer these questions. Patients will be treated with a low dose (5 mg) of ketamine nasal spray and then measure its effectiveness, practicality and safety. Questionnaires will be used to measure these outcomes. If treating depression and anxiety with ketamine nasal spray proves to be effective, practical and safe, then it could help to improve the quality of life for palliative care patients and reduce the burden of their caregivers.
Trial Details
NCT Number NCT06665568
Lead Sponsor University of Zurich
Conditions Depressive Symptoms Mild to Moderate in Severity, Anxiety, Quality of Life (QOL), Caregiver Burden, Sleep Quality
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov